THL Credit TCRX 深 沪
等待开盘 10-11 09:30:00 美东时间
2.21
+0.040
+1.84%
华盛通- 最 高2.33
- 今 开2.20
- 成交量 104.83万股
- 最 低 2.03
- 昨 收 2.17
- 总市值 1.25亿
- 52周最高 6.225
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.02
- 委 比 -55.93%
- 总股本 5674.80万
- 历史最高 14.71
- 量 比 1.26
- 振 幅 13.82%
- 历史最低 1.02
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TScan Therapeutics To Present New Research On T Cell Therapies At ACR Convergence 2025 In Chicago
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today
09-17 19:03
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
<p>TScan Therapeutics announced the acceptance of two abstracts for presentation at the ACR Convergence 2025, highlighting novel T cell targets in autoimmune disorders like Ankylosing Spondylitis using their TargetScan technology. The findings aim to advance therapies for these conditions.</p>
09-17 11:00
TScan Therapeutics to Participate in Upcoming Investor Conferences
<p>TScan Therapeutics announced participation in upcoming investor conferences: the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 9 and the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 10. Webcasts will be available on the company's website, ir.tscan.com, with replays accessible for 90 days. TScan focuses on developing TCR-engineered T cell therapies for cancer treatment.</p><br>
09-03 11:00
TScan Therapeutics Q2 EPS $(0.28), Inline, Sales $3.076M Beat $1.405M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $3.076
08-12 19:12
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics reported Q2 2025 financial results, including revenue of $3.1 million, R&D expenses of $32.6 million, and a net loss of $37.0 million. The company announced plans to treat first solid tumor patients with multiplex TCR-T therapy in Q3 2025 and expects to present two-year relapse data from the ALLOHA™ Phase 1 trial by year-end. Cash reserves of $218 million are sufficient to fund operations into Q1 2027.
08-12 11:00
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics, Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 4:55 p.m. ET in New York. A webcast will be available on the company’s website, ir.tscan.com, with an archived replay for 90 days. TScan is a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment. The company is currently enrolling patients in two clinical programs: ALLOHA™ for hematologic malignancies a...
05-28 11:00
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.
05-07 20:26
TScan Therapeutics GAAP EPS of $0.26
TScan Therapeutics press release (NASDAQ:TCRX): Q1 GAAP EPS of $0.26. Revenue of $2.2M beats by $1.12M. More on TScan Therapeutics TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 TScan Ther...
05-06 23:13
美股大行评级 | 潜在涨幅147.43%！HC Wainwright & Co.上调Pacira BioSciences目标价至65美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116650478822592513.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Pacira BioSciences(PCRX)"买入"评级，目标价从48美元升至65美元</p> <p>• 瑞穗：上调Amylyx Pharmaceuticals(AM
04-09 08:50
